vs
Side-by-side financial comparison of Dianthus Therapeutics, Inc. (DNTH) and PROTHENA CORP PUBLIC LTD CO (PRTA). Click either name above to swap in a different company.
Dianthus Therapeutics, Inc. is the larger business by last-quarter revenue ($284.0K vs $21.0K, roughly 13.5× PROTHENA CORP PUBLIC LTD CO). On growth, Dianthus Therapeutics, Inc. posted the faster year-over-year revenue change (-78.6% vs -99.0%). Over the past eight quarters, PROTHENA CORP PUBLIC LTD CO's revenue compounded faster (-35.2% CAGR vs -44.6%).
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
DNTH vs PRTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0K | $21.0K |
| Net Profit | $-64.4M | — |
| Gross Margin | — | — |
| Operating Margin | -24486.3% | — |
| Net Margin | -22687.3% | — |
| Revenue YoY | -78.6% | -99.0% |
| Net Profit YoY | -126.6% | 62.7% |
| EPS (diluted) | $-1.53 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0K | $21.0K | ||
| Q3 25 | $396.0K | $2.4M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | $1.2M | $2.8M | ||
| Q4 24 | $1.3M | $2.1M | ||
| Q3 24 | $2.2M | $970.0K | ||
| Q2 24 | $1.9M | $132.0M | ||
| Q1 24 | $874.0K | $50.0K |
| Q4 25 | $-64.4M | — | ||
| Q3 25 | $-36.8M | $-36.5M | ||
| Q2 25 | — | $-125.8M | ||
| Q1 25 | $-29.5M | $-60.2M | ||
| Q4 24 | $-28.4M | — | ||
| Q3 24 | $-25.2M | $-59.0M | ||
| Q2 24 | $-17.6M | $66.9M | ||
| Q1 24 | $-13.7M | $-72.2M |
| Q4 25 | -24486.3% | — | ||
| Q3 25 | -10173.7% | -1666.3% | ||
| Q2 25 | — | -1914.4% | ||
| Q1 25 | -2852.7% | -2319.0% | ||
| Q4 24 | -2406.9% | — | ||
| Q3 24 | -1376.6% | -6857.0% | ||
| Q2 24 | -1191.8% | 44.2% | ||
| Q1 24 | -2041.6% | -163056.0% |
| Q4 25 | -22687.3% | — | ||
| Q3 25 | -9284.1% | -1513.1% | ||
| Q2 25 | — | -2845.4% | ||
| Q1 25 | -2537.5% | -2128.5% | ||
| Q4 24 | -2144.8% | — | ||
| Q3 24 | -1159.0% | -6082.6% | ||
| Q2 24 | -945.1% | 50.7% | ||
| Q1 24 | -1573.0% | -144478.0% |
| Q4 25 | $-1.53 | — | ||
| Q3 25 | $-0.97 | $-0.68 | ||
| Q2 25 | — | $-2.34 | ||
| Q1 25 | $-0.82 | $-1.12 | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.74 | $-1.10 | ||
| Q2 24 | $-0.51 | $1.22 | ||
| Q1 24 | $-0.54 | $-1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $404.3M | $307.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $493.4M | $280.5M |
| Total Assets | $530.9M | $326.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $404.3M | $307.5M | ||
| Q3 25 | $402.6M | $330.8M | ||
| Q2 25 | — | $371.4M | ||
| Q1 25 | $263.2M | $417.9M | ||
| Q4 24 | $275.2M | $471.4M | ||
| Q3 24 | $281.1M | $519.3M | ||
| Q2 24 | $360.7M | $564.1M | ||
| Q1 24 | $377.0M | $546.5M |
| Q4 25 | $493.4M | $280.5M | ||
| Q3 25 | $546.5M | $295.0M | ||
| Q2 25 | — | $324.3M | ||
| Q1 25 | $328.6M | $437.7M | ||
| Q4 24 | $352.5M | $486.9M | ||
| Q3 24 | $337.9M | $534.4M | ||
| Q2 24 | $358.2M | $581.9M | ||
| Q1 24 | $372.7M | $502.4M |
| Q4 25 | $530.9M | $326.8M | ||
| Q3 25 | $577.4M | $352.6M | ||
| Q2 25 | — | $399.1M | ||
| Q1 25 | $348.6M | $495.3M | ||
| Q4 24 | $374.0M | $547.1M | ||
| Q3 24 | $354.2M | $595.3M | ||
| Q2 24 | $369.0M | $645.6M | ||
| Q1 24 | $382.5M | $623.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.0M | $-163.6M |
| Free Cash FlowOCF − Capex | $-47.1M | — |
| FCF MarginFCF / Revenue | -16591.9% | — |
| Capex IntensityCapex / Revenue | 48.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-132.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.0M | $-163.6M | ||
| Q3 25 | $-30.6M | $-40.6M | ||
| Q2 25 | — | $-46.3M | ||
| Q1 25 | $-27.6M | $-53.4M | ||
| Q4 24 | $-27.4M | $-150.1M | ||
| Q3 24 | $-21.3M | $-45.2M | ||
| Q2 24 | $-14.5M | $16.0M | ||
| Q1 24 | $-14.9M | $-73.1M |
| Q4 25 | $-47.1M | — | ||
| Q3 25 | $-30.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-27.5M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-14.5M | — | ||
| Q1 24 | $-15.0M | — |
| Q4 25 | -16591.9% | — | ||
| Q3 25 | -7717.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -2377.8% | — | ||
| Q4 24 | -2072.0% | — | ||
| Q3 24 | -980.3% | — | ||
| Q2 24 | -780.7% | — | ||
| Q1 24 | -1713.2% | — |
| Q4 25 | 48.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 3.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
